Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630309 | 1.00 | ACHE (0.50) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL3630177 | 0.97 | ACHE (0.46) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL145689 | 0.89 | ACHE (0.54) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL31427641 | 0.89 | ACHE (0.54) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL31427640 | 0.89 | ACHE (0.54) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL159389 | 0.89 | ACHE (0.54) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL158755 | 0.89 | ACHE (0.54) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL28508461 | 0.87 | ACHE (0.41) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL269923 | 0.86 | ACHE (0.44) | ACHENPSR1MEN1KMT2ALMNA | |
| SCHEMBL156375 | 0.86 | ACHE (0.50) | ACHENPSR1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858661-B2 | Protein refolding agent and refolding method | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100168403-A1 | Protein refolding agent and refolding method | YAMAGUCHI SHUNICHLRO | 2010-07-01 | — | — | US | disclosed |
| US-7709409-B2 | Mixed catalytic composition | CHEMTURA ORGANOMETALLICS GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20070179045-A1 | Mixed catalytic composition | PMC VLISSINGEN NETHERLANDS, B.V. (NL) | 2007-08-02 | — | — | US | disclosed |
| US-20060052575-A1 | Mixed catalyst composition | CHEMTURA ORGANOMETALLICS GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1567473-A1 | MIXED CATALYTIC COMPOSITION | Crompton GmbH (DE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050597-A1 | MIXED CATALYTIC COMPOSITION | CROMPTON GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | HSPA5, HSPBP1, RRBP1 | ACHE 1671/4885NPSR1 4619/4885MEN1 4880/4885 |
| US-20100168403-A1 | Protein refolding agent and refolding method | HSPA5, HSPBP1, RRBP1 | ACHE 1709/4885NPSR1 4607/4885MEN1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.